Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

Summary

A Simply Wall St-style article reports that the fair value estimate for Summit Therapeutics stock edged higher following an AstraZeneca deal and a focus on its clinical trials. The article text provided includes no specific deal terms, trial data, or financial figures.